- Home
- KZIA vs SILO Comparison
KZIA vs SILO Comparison
Compare KZIA & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- SILO
- Stock Information
- Founded
- KZIA 1994
- SILO 2010
- Country
- KZIA Australia
- SILO United States
- Employees
- KZIA N/A
- SILO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- KZIA Health Care
- SILO Consumer Discretionary
- Exchange
- KZIA Nasdaq
- SILO Nasdaq
- Market Cap
- KZIA 9.0M
- SILO 7.3M
- IPO Year
- KZIA 1999
- SILO N/A
- Fundamental
- Price
- KZIA $7.20
- SILO $0.70
- Analyst Decision
- KZIA Strong Buy
- SILO
- Analyst Count
- KZIA 3
- SILO 0
- Target Price
- KZIA $16.00
- SILO N/A
- AVG Volume (30 Days)
- KZIA 299.1K
- SILO 3.1M
- Earning Date
- KZIA 11-14-2025
- SILO 11-11-2025
- Dividend Yield
- KZIA N/A
- SILO N/A
- EPS Growth
- KZIA N/A
- SILO N/A
- EPS
- KZIA N/A
- SILO N/A
- Revenue
- KZIA $1,549,158.00
- SILO $72,102.00
- Revenue This Year
- KZIA N/A
- SILO $1.86
- Revenue Next Year
- KZIA $49.25
- SILO N/A
- P/E Ratio
- KZIA N/A
- SILO N/A
- Revenue Growth
- KZIA 248983.08
- SILO N/A
- 52 Week Low
- KZIA $2.86
- SILO $0.41
- 52 Week High
- KZIA $39.05
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- KZIA 43.08
- SILO 47.34
- Support Level
- KZIA $6.20
- SILO $0.66
- Resistance Level
- KZIA $7.61
- SILO $0.71
- Average True Range (ATR)
- KZIA 0.48
- SILO 0.07
- MACD
- KZIA -0.06
- SILO -0.01
- Stochastic Oscillator
- KZIA 47.57
- SILO 6.90
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.